DGAP-Adhoc: Dermapharm Holding SE acquires a stake in cannabis producer for pharmaceutical applications

2019. március 04., hétfő, 17:51





DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Investment


Dermapharm Holding SE acquires a stake in cannabis producer for pharmaceutical applications


04-March-2019 / 17:51 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Disclosure of insider information pursuant to Section 17 (1) 1 of the EU Regulation

no. 596/2014 on market abuse as amended (Market Abuse Regulation - MAR)



Dermapharm Holding SE acquires a stake in cannabis producer for pharmaceutical applications



Grünwald, March 4, 2019 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) concluded an agreement today to acquire a stake in the companies FYTA Company B.V. and FYTA Tech B.V., both headquartered in Waalwijk, Netherlands, as well as FYTA Company GmbH and FYTA Vermögensverwaltung GmbH, both headquartered in Monheim, Germany. By signing the contract, Dermapharm Holding SE is acquiring 20.00 percent of the shares in the companies specializing in the production of medical cannabis for pharmaceutical applications with effect from March 4, 2019. The parties have agreed not to disclose the purchase price. The approval required for medical cannabis production was granted by the Dutch regulatory authority (CIBG)(1) on February 25, 2019. The approval covers around 12 tons of medical cannabis per year and is expandable. FYTA currently has its own state-of-the-art indoor production facility in Waalwijk that enables the production of up to 25 tons of medical cannabis per year. The transaction also includes the assignment of 49.9% of the shares in the 100% axicorp subsidiary Remedix GmbH, based in Friedrichsdorf, Germany, to UWF Beteiligungsgesellschaft mbH, based in Monheim, Germany. As a re-importer in the pharmaceutical sector, Remedix GmbH is specialized in EU narcotics and licensed by the Federal Opium Agency to trade in narcotics. Remedix GmbH will take over the import to Germany and distribution of medical cannabis as a joint platform between Dermapharm and the FYTA companies.



1) Ministerie von Volksgezondheid, Welzijn en Sport



>End of ad hoc announcement<



 



Contacts





Investor Relations

Britta Hamberger

Phone: +49 (0)89 - 64186-233

Fax: +49 (0)89 - 64186-165

email: ir@dermapharm.com
cometis AG

Claudius Krause

Phone: +49 (0)611 - 205855-28

Fax: +49 (0)611 - 205855-66

email: ir@dermapharm.com








04-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de























Language: English
Company: Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.de
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange





 
End of Announcement DGAP News Service




783577  04-March-2019 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=783577&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.